Dosage and Administration |
3/2019 |
Warnings and Precautions, Embryo-Fetal Toxicity |
12/2018 |
|
|
|
|
|
Recommended dose | 1 injection every 4 weeks | 1 injection every 12 weeks | 1 injection every 16 weeks | 1 injection every 24 weeks |
|
||
|
||
|
|
|
|
||
General pain | 13 | (23.2) |
Infection | 3 | (5.4) |
|
||
Hot flashes/sweats* | 32 | (57.1) |
|
||
GI disorders | 8 | (14.3) |
|
||
Edema | 8 | (14.3) |
|
||
Libido decreased* | 3 | (5.4) |
|
||
Respiratory disorder | 6 | (10.7) |
|
||
Urinary disorder | 7 | (12.5) |
Impotence* | 3 | (5.4) |
Testicular atrophy* | 3 | (5.4) |
* Due to the expected physiologic effect of decreased testosterone levels. |
|
||
|
||
|
|
|
|
||
Asthenia | 7 | (7.4) |
General Pain | 25 | (26.6) |
Headache | 6 | (6.4) |
Injection Site Reaction | 13 | (13.8) |
|
||
Hot flashes/Sweats | 55 | (58.5) |
|
||
GI Disorders | 15 | (16.0) |
|
||
Joint Disorders | 11 | (11.7) |
|
||
Dizziness/Vertigo | 6 | (6.4) |
Insomnia/Sleep Disorders | 8 | (8.5) |
Neuromuscular Disorders | 9 | (9.6) |
|
||
Respiratory Disorders | 6 | (6.4) |
|
||
Skin Reaction | 8 | (8.5) |
|
||
Testicular Atrophy | 19 | (20.2) |
Urinary Disorders | 14 | (14.9) |
|
||||
|
||||
|
|
|
||
|
|
|||
|
|
|
|
|
|
||||
Asthenia | 6 | (12.2) | 1 | (4.2) |
Flu Syndrome | 6 | (12.2) | 0 | (0.0) |
General Pain | 16 | (32.7) | 1 | (4.2) |
Headache | 5 | (10.2) | 1 | (4.2) |
Injection Site Reaction | 4 | (8.2) | 9 | (37.5) |
|
||||
Hot flashes/Sweats | 23 | (46.9) | 2 | (8.3) |
|
||||
GI Disorders | 5 | (10.2) | 3 | (12.5) |
|
||||
Dehydration | 4 | (8.2) | 0 | (0.0) |
Edema | 4 | (8.2) | 5 | (20.8) |
|
||||
Joint Disorder | 8 | (16.3) | 1 | (4.2) |
Myalgia | 4 | (8.2) | 0 | (0.0) |
|
||||
Dizziness/Vertigo | 3 | (6.1) | 2 | (8.3) |
Neuromuscular Disorders | 3 | (6.1) | 1 | (4.2) |
Paresthesia | 4 | (8.2) | 1 | (4.2) |
|
||||
Respiratory Disorder | 4 | (8.2) | 1 | (4.2) |
|
||||
Skin Reaction | 6 | (12.2) | 0 | (0.0) |
|
||||
Urinary Disorders | 5 | (10.2) | 4 | (16.7) |
|
||||
|
||||
|
|
|||
|
|
|
|
|
Hot Flush/Flushing | 89 | 58.9 | 88 | 58.3 |
Injection Site Pain/Discomfort | 29 | 19.2 | 16 | 10.6 |
Upper Respiratory Tract Infection/Influenza-like Illness1 | 32 | 21.2 | 0 | 0 |
Fatigue/Lethargy | 20 | 13.2 | 18 | 11.9 |
Constipation | 15 | 9.9 | 5 | 3.3 |
Arthralgia | 14 | 9.3 | 2 | 1.3 |
Insomnia/Sleep Disorder | 13 | 8.6 | 5 | 3.3 |
Headache/Sinus Headache | 12 | 7.9 | 3 | 2.0 |
Musculoskeletal Pain/ Myalgia | 12 | 7.9 | 3 | 2.0 |
Second Primary Neoplasm2 | 11 | 7.3 | 0 | 0 |
Cough | 10 | 6.6 | 2 | 1.3 |
Hematuria/Hemorrhagic Cystitis | 10 | 6.6 | 0 | 0 |
Hypertension/BP Increased | 10 | 6.6 | 3 | 2.0 |
Rash | 9 | 6.0 | 3 | 2.0 |
Dysuria | 9 | 6.0 | 1 | 0.7 |
Urinary Tract Infection/Cystitis | 9 | 6.0 | 0 | 0 |
Anemia/Hemoglobin Decreased | 10 | 6.6 | 2 | 1.3 |
Back Pain | 8 | 5.3 | 0 | 0 |
COPD | 8 | 5.3 | 0 | 0 |
Dizziness | 8 | 5.3 | 3 | 2.0 |
Dyspnea/Dyspnea on Exertion | 8 | 5.3 | 2 | 1.3 |
Nocturia | 8 | 5.3 | 2 | 1.3 |
Peripheral/Pitting Edema | 8 | 5.3 | 2 | 1.3 |
Coronary Artery Disease/Angina | 8 | 5.3 | 1 | 0.7 |